Narrow search
Showing 1 - 10 of 36,348
Cover Image
Cost Effectiveness of Rituximab for Non-Hodgkin's Lymphoma: A Systematic Review
Auweiler, Philipp W.P.; Muller, Dirk Mller; Stock, Stephanie - In: PharmacoEconomics 30 (2012) 7, pp. 537-549
Background:Background: The monoclonal antibody rituximab has shown clinical effectiveness in combination with … chemotherapy for the treatment of non-Hodgkin's lymphoma (NHL) in several randomized controlled studies. Rituximab maintenance …, treatment with rituximab causes considerable costs for healthcare systems. Abstract: Objective:Objective: This article provides …
Persistent link: https://www.econbiz.de/10010551727
Cover Image
Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura: A NICE Single Technology Appraisal
Boyers, Dwayne; Jia, Xueli; Jenkinson, David; Mowatt, Graham - In: PharmacoEconomics 30 (2012) 6, pp. 483-495
to 2 years and prescribing eltrombopag as second-line treatment post-rituximab were found to be favourable towards … eltrombopag. As rituximab is not a licensed treatment for ITP, the ERG were concerned that its inclusion may not be reflective of …
Persistent link: https://www.econbiz.de/10010548287
Cover Image
Quality-of-Life Assessment in Rheumatoid Arthritis
Russell, Anthony S. - In: PharmacoEconomics 26 (2008) 10, pp. 831-846
Rheumatoid arthritis (RA) is a chronic and lifelong autoimmune disorder that results in significant pain, disability and excess mortality if untreated or inadequately treated. Quality-of-life (QOL) assessments are particularly important in the absence of a cure for RA. Generic and...
Persistent link: https://www.econbiz.de/10005404851
Cover Image
Advances in Cancer Therapeutics and Patient Access to New Drugs
Dranitsaris, George; Truter, Ilse; Lubbe, Martie S.; … - In: PharmacoEconomics 29 (2011) 3, pp. 213-224
Globally, there are approximately 7.4 million cancer deaths annually, approximately 13% of deaths from all causes. Cancer is a disease of older people and, as the population ages over the next 10-20 years, we can expect an increase in the cancer incidence. Encouragingly, cancer mortality has...
Persistent link: https://www.econbiz.de/10010614407
Cover Image
Erratum
Adis International Limited - In: PharmacoEconomics 30 (2012) 1, pp. 81-81
Persistent link: https://www.econbiz.de/10009421259
Cover Image
Cost Effectiveness of Drug-Eluting Stents in Acute Myocardial Infarction Patients in Germany: Results from Administrative Data Using a Propensity Score-Matching Approach
Baumler, Michael Bumler; Stargardt, Tom; Schreyogg, … - In: Applied Health Economics and Health Policy 10 (2012) 4, pp. 235-248
Background:Background: The high number of patients with acute myocardial infarction (AMI) has facilitated greater research, resulting in the development of innovative medical devices. So far, results from economic evaluations that compared drug-eluting stents (DES) and bare-metal stents (BMS)...
Persistent link: https://www.econbiz.de/10011005060
Cover Image
Cost Effectiveness of Prostacyclins in Pulmonary Arterial Hypertension
Roman, Antonio; Barberà, Joan A. Barber; Escribano, Pilar - In: Applied Health Economics and Health Policy 10 (2012) 3, pp. 175-188
Background:Background: Pulmonary arterial hypertension (PAH) is considered an orphan disease. Prostacyclins are the keystone for PAH treatment. Choosing between the three available prostacyclin therapies could be complicated because there are no comparison studies, so the final decision must be...
Persistent link: https://www.econbiz.de/10011005061
Cover Image
Cost-Effectiveness Analysis of Early versus Non-Early Intervention in Acute Migraine Based on Evidence from the 'Act when Mild' Study
Slof, John - In: Applied Health Economics and Health Policy 10 (2012) 3, pp. 201-215
Background:Background: In spite of the important progress made in the abortive treatment of acute migraine episodes since the introduction of triptans, reduction of pain and associated symptoms is in many cases still not as effective nor as fast as would be desirable. Recent research pays more...
Persistent link: https://www.econbiz.de/10011005063
Cover Image
Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer: A Systematic Review
Bongers, Mathilda L.; Coupé, Veerle M.H. Coup; Jansma, … - In: PharmacoEconomics 30 (2012) 1, pp. 17-34
In past decades, studies focusing on new chemotherapeutic agents for patients with inoperable non-small-cell lung cancer have reported only modest gains in survival. These health gains are achieved at considerable cost, but economic evidence is lacking on superiority of one agent in terms of...
Persistent link: https://www.econbiz.de/10011005070
Cover Image
Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis
Soares, Marta O.; Canto e Castro, Lusa - In: PharmacoEconomics 30 (2012) 12, pp. 1101-1117
The design of decision-analytic models for cost-effectiveness analysis has been the subject of discussion. The current work addresses this issue by noting that, when time is to be explicitly modelled, we need to represent phenomena occurring in continuous time. Models evaluated in continuous...
Persistent link: https://www.econbiz.de/10011005076